Propanc Biopharma announced preclinical research revealing that its pancreatic proenzyme formulation, PRP, can remodel chemotherapy-resistant pancreatic cancer cells, making them more vulnerable to subsequent chemotherapy. The study demonstrated that PRP treatment reduces cancer cell proliferation, suppresses metastatic behavior, reverses cellular plasticity linked to resistance, and induces apoptosis. These findings support PRP's potential as a resistance-modulating therapy to be tested in a Phase 1b clinical trial starting Q1 2027, aiming to improve outcomes for patients with advanced solid tumors by overcoming treatment resistance.
Propanc Biopharma's lead asset PRP is the subject, with Pluang's Health-sector market data providing context. As of Oct 16, 2026 19:01 WIB, 93 of 150 priced Health-sector US stocks rose while 46 fell. Amneal Pharmaceuticals Inc. Class A Common Stock (AMRX) traded at USD 19.50 with a 1-day change of +1.30%, Canopy Growth Corp (CGC) was priced at USD 0.74 with Pluang order activity showing 100% Sell, and Tilray Brands Inc (TLRY) traded at USD 3.25 with 97% Sell activity.
Whole Lotta Dank, a Canadian cannabis brand platform, has launched its first brand, Dank Pack, debuting with Blueberry BBL available across Alberta. The company is expanding its portfolio with over 20 SKUs under regulatory review and is actively seek...
Nasdaq announced that trading in CN Healthy Food Tech Group Corp.'s common stock and warrants will resume on October 19, 2026, after being halted since October 1, 2025. The resumption marks the end of a year-long trading suspension, allowing investor...
David Solomon, CEO of Goldman Sachs, has been appointed as the new chair of The Business Council, taking over from Brian Cornell, Executive Chair of Target Corporation. This leadership change comes at a critical time as the Council addresses challeng...
The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, expanding at a CAGR of 6.15%. Growth is fueled by advances in biologics, AI-driven drug discovery, specialty drugs, and manufacturing i...
SEDA Experts LLC has appointed Noor Ul Islam as Managing Director, enhancing its capabilities in risk management and securities practices. With nearly 30 years of experience at major financial institutions like Citibank and Barclays, Islam brings dee...
